NCT04669067: An ongoing trial by Telios Pharma, Inc.
This trial is ongoing. It must report results 4 months, 2 weeks from now.
Full data
Full entry on ClinicalTrials.gov | NCT04669067 |
---|---|
Title | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML) |
Results Status | Ongoing |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | March 31, 2021 |
Completion date | Nov. 30, 2024 |
Required reporting date | Nov. 30, 2025, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | July 16, 2025 |
Days late | None |